Adobe Stock
Biocon’s stock got a sugar rush this week.
On Wednesday (July 16, 2025), shares of the biotech major jumped nearly 2 per cent to Rs 397 after its insulin aspart injection (Kirsty) received the green light from the USFDA. That makes it one of the most active names on the bourses, clocking nearly Rs 400 crore in traded value on the NSE alone.
But is this just a sugar high or something more sustainable?
What’s driving the stock
There are two reasons investors are buzzing:
- FDA approval for insulin aspart (Kirsty): This opens up a sizeable addressable market in the US. With diabetes on the rise and cost pressure on US healthcare providers, low-cost biosimilars like Biocon’s are gaining traction.
- Volume surge: The stock saw unusually high trading volumes, signalling institutional interest and possibly some short covering. It follows another positive trigger from last month when Biocon secured Indian drug regulator (CDSCO) approval for liraglutide, another diabetes drug.
What Biocon does
Biocon is India’s largest biopharma player with global ambitions. It focuses on biosimilars, generics, and novel biologics, especially in chronic disease segments like diabetes, cancer and autoimmune disorders. Its key strength lies in affordable innovation, and its subsidiary, Biocon Biologics, is the engine powering its global push, especially in the regulated US and EU markets.
Here’s how Biocon stacks up on key metrics.
| Metric | Value |
|---|---|
| Market cap | Rs 52,168 crore |
| P/E ratio | 51.5 |
| P/B ratio | 2 |
| EPS | Rs 8.2 |
| ROE | 7 per cent |
| ROCE | 7 per cent |
| Book value | Rs 195.5 |
| Dividend yield | 0.1 per cent |
Value Research Online ratings
- Overall: 2/5
- Quality: 2/10
- Growth: 8/10
- Valuation: 3/10
- Momentum: 5/10
The takeaway
Biocon’s stock has caught a tailwind, thanks to a regulatory boost. But with fundamentals still catching up and the price already rich, investors may want to avoid chasing the rally blindly. Keep it on your radar—but maybe not in your cart just yet.
Serious about wealth? So are we.
Join thousands of smart investors who rely on Value Research Stock Advisor for expert-picked stocks, time-tested strategies and long-term discipline.
Stop guessing. Start growing. Check it out now: Value Research Stock Advisor.
Disclaimer: This is not a stock recommendation. This story was created with the assistance of artificial intelligence and has been reviewed by human experts for accuracy and is intended for informational purposes only. Please take it with a pinch of salt and do your own research or consult a financial advisor before making investment decisions.
Ask Value Research 
New episodes every Friday 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
